![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol. , 22 June 2021
Sec. Molecular and Cellular Oncology
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.718849
This article is part of the Research Topic Therapeutic Prospects of Targeting Invadopodia to Halt Cancer Metastasis View all 4 articles
This article is a correction to:
A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells
A Corrigendum on
A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells
By Huang S-S, Liao W-Y, Hsu C-C, Chan T-S, Liao T-Y, Yang P-M, Chen L-T, Sung S-Y and Tsai KK (2021). Front. Oncol. 11:638311. doi: 10.3389/fonc.2021.638311
In the original article, there was a mistake in the legend for Figure 3 as published. The name of the mouse strain described in (A) and (C) was mis-spelled as “NOC/SCID”, which should be “NOD/SCID”. Appended below is the corrected legend.
Figure 3 sENO1+ CSCs are highly pro-metastatic. (A) Representative BLI of NOD/SCID mice receiving an intra-splenic injection of sENO1+ CSCs (represented by CD90+ NCI-N87 cells), sENO1- CSCs (CD90- NCI-N87 cells), and non-CSCs (represented by CD90- cells). at the indicated time following cell inoculation. (B) Tumor bulk quantified as BLI normalized photon counts as a function of time. Error bars represent mean ± SEM from one experiment (n = 8 mice per group). Unpaired t-test was performed throughout where **p < 0.01 versus non-CSCs. (C) Representative BLI of NOD/SCID mice receiving intra-splenic injection of sENO1+CSCs (represented by CD90+ MKN-45 cells), sENO1- CSCs (CD90- MKN-45 cells) and non-CSCs (represented by CD90- cells). at the indicated time following cell inoculation. (D) Tumor bulk quantified as BLI normalized photon counts as a function of time. Error bars represent mean ± SEM from one experiment (n = 8 mice per group). Unpaired t-test was performed throughout where *p < 0.05 versus non-CSCs.
In the original article, there was a mistake in the legend for Figure 4 as published. We mislabeled the name of the cell line in (B) as “NCI-N87”, which should be “AGS” as described in the main text. Appended below is the corrected legend.
Figure 4 ENO1 is expressed on the invadopodial surface of CSCs. (A) Confocal views of PAC CSCs (represented by CD44+CD133+ PC-3 cells) showing the cross-section of invadopodia structures (represented by cortactin+F-acin+ puncta) with the colocalized surface ENO1 (sENO1; green), cortactin (red), and F-actin (magenta) that penetrate into the underlying gelatin matrix. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI; blue). Scale, 10 μm. (B) Top, a pie chart showing the percentage of sENO1+ invadopodia per PC-3 CSC. Bottom, a pie chart showing the percentage of sENO1+ invadopodia per GAC AGS CSC (represented by CD90+ AGS cells). (C) Left, representative three-dimensional (3D) reconstructed confocal image of CD44+CD133+ PC-3 CSCs showing the colocalization of sENO1 (green) and cortactin (red) at the ventral side of cell. Scale, 8 μm. Right upper, digital zoom-in image from serial Z sections (yellow rectangle) showing the spatial colocalization of sENO1 (green) and cortactin (red) at invadopodia. Scale, 5 μm. Right lower, the orthogonal view of the magnified areas (yellow squares at top) shown the distribution and localization of sENO1 and cortactin at the base of invadopodia. 3D rendered images of the invadopodia (arrows) were processed by using Imaris software. Scale, 1 μm.
In the original article, there was a mistake in Figure 4 as published. We mislabeled the name of the cell line as “NCI-N87” at the lower panel of Figure 4B, which should be “AGS” as described in the main text. We mark the right name in the red rectangle in the corrected figure below.
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way.
Keywords: ENO1, metastasis, cancer stem cells, invadopodia, prostate cancer, gastric cancer
Citation: Huang S-S, Liao W-Y, Hsu C-C, Chan T-S, Liao T-Y, Yang P-M, Chen L-T, Sung S-Y and Tsai KK (2021) Corrigendum: A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells. Front. Oncol. 11:718849. doi: 10.3389/fonc.2021.718849
Received: 01 June 2021; Accepted: 10 June 2021;
Published: 22 June 2021.
Edited and reviewed by:
Laura Rosanò, Institute of Molecular Biology and Pathology (CNR), ItalyCopyright © 2021 Huang, Liao, Hsu, Chan, Liao, Yang, Chen, Sung and Tsai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kelvin K. Tsai, dHNhaWtAdG11LmVkdS50dw==
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.